At the news
? BULLISHIMPACT 7/10 6-K filed Jul 17, 2026 at 07:31 ET
Evaxion announced it will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ESMO Congress in October 2026. The data from a phase 2 trial extension will show EVX-01's effect as a stand-alone therapy in advanced melanoma patients, building on previously reported two-year results showing a 75% objective response rate and durable responses. The presentation is a key catalyst for the stock, as positive data could support partnership discussions and late-stage development plans for this lead asset.
- Evaxion will present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 (October 23-27, 2026) in Madrid.
- The data comes from a one-year extension of the phase 2 trial where patients received EVX-01 as stand-alone therapy (without anti-PD-1 combination).
- Previously reported two-year data showed a 75% Objective Response Rate (ORR) with 12 of 16 patients responding, including 4 complete responses, and 92% of patients still responding at two years with no relapses.
- EVX-01 induced an immune response in all patients, with 86% of targeted neoantigens generating potent T-cell responses.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access